Vaccine and monoclonal antibody that enhance mouse resistance to candidiasis

Clinical and Vaccine Immunology

Volumn 18, Issue 10, 2011, Pages 1656-1667

  Xin, Hong ^a   Cutler, Jim E ^a  

^a LOUISIANA STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALUMINUM POTASSIUM SULFATE; DENDRITIC CELL VACCINE; FRUCTOSE BISPHOSPHATE ALDOLASE; IMMUNOGLOBULIN M ANTIBODY; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY E2 9; PHOSPHORYL LIPID A; UNCLASSIFIED DRUG;

ADJUVANT THERAPY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY PRODUCTION; ANTIBODY RESPONSE; ARTICLE; CANDIDA ALBICANS; CANDIDIASIS; CELL SURFACE; CONTROLLED STUDY; FEMALE; FUNGAL STRAIN; HAPLOTYPE; IMMUNOGENICITY; INFECTION RESISTANCE; INVASIVE CANDIDIASIS; MOUSE; NONHUMAN; PASSIVE IMMUNIZATION; PRIORITY JOURNAL; RABBIT;

ANIMALS; ANTIBODIES, FUNGAL; ANTIBODIES, MONOCLONAL; ANTIGENS, FUNGAL; CANDIDA ALBICANS; CANDIDIASIS; DENDRITIC CELLS; DISEASE MODELS, ANIMAL; FUNGAL VACCINES; IMMUNOTHERAPY; MICE; SURVIVAL ANALYSIS; VACCINES, CONJUGATE;

EID: 80053442336     PISSN: 15566811     EISSN: 1556679X     Source Type: Journal    
DOI: 10.1128/CVI.05215-11     Document Type: Article

References (54)

1. Antonsson, A., and P. J. H. Johansson. 2001. Binding of human and animal immunoglobulins to the IgG Fc receptor induced by human cytomegalovirus. J. Gen. Virol. 82:1137-1145. (Pubitemid 32454613)
2. Ashman, R. B. 1987. Mouse candidiasis. II. Host responses are T-cell dependent and regulated by genes in the major histocompatibility complex. Immunogenetics 25:200-203. (Pubitemid 17034820)
3. Ashman, R. B. 1990. Murine candidiasis: susceptibility is associated with the induction of T cell-mediated, strain-specific autoreactivity. Immunol. Cell Biol. 68:179-185. (Pubitemid 20300152)
4. Ashman, R. B., and J. M. Papadimitriou. 1987. Murine candidiasis. Pathogenesis and host responses in genetically distinct inbred mice. Immunol. Cell Biol. 65:163-171. (Pubitemid 18045019)
5. Brena, S., et al. 2007. Fungicidal monoclonal antibody C7 binds to Candida albicans. Infect. Immun. 75:3680-3682. (Pubitemid 47040972)
6. Brett, S. J., and R. Butler. 1988. Macrophage activity in resistant and susceptible mouse strains infected with Mycobacterium lepraemurium. Immunology 63:701-706.
7. Cabezas, J., et al. 2010. Potential of anti-Candida antibodies in immunoprophylaxis. Immunotherapy 2:171-183.
8. Casadevall, A., E. Dadachova, and L.-A. Pirofski. 2004. Passive antibody therapy for infectious diseases. Nat. Rev. 2:695-703. (Pubitemid 39200062)
9. Casadevall, A., and L.-A. Pirofski. 2007. Antibody-mediated protection through cross-reactivity introduces a fungal heresy into immunological dogma. Infect. Immun. 75:5074-5078. (Pubitemid 350033593)
10. Cassone, A., F. De Bernardis, and A. Torosantucci. 2005. An outline of the role of anti-Candida antibodies within the context of passive immunization and protection from candidiasis. Curr. Mol. Med. 5:377-382. (Pubitemid 40846918)
11. Clancy, C. J., et al. 2008. Immunoglobulin G responses to a panel of Candida albicans antigens as accurate and early markers for the presence of systemic candidiasis. J. Clin. Microbiol. 46:1647-1654. (Pubitemid 351657208)
12. Reference deleted.
13. Cutler, J. E. 2005. Defining criteria for anti-mannan antibodies to protect against candidiasis. Curr. Mol. Med. 5:383-392. (Pubitemid 40846919)
14. Reference deleted.
15. Cutler, J. E., G. S. Deepe, Jr., and B. S. Klein. 2007. Advances in combating fungal diseases: vaccines on the threshold. Nat. Rev. Microbiol. 5:13-28. (Pubitemid 44942300)
16. Reference deleted.
17. De Bernardis, F., et al. 1997. Protective role of antimannan and anti-aspartyl proteinase antibodies in an experimental model of Candida albicans vaginitis in rats. Infect. Immun. 65:3399-3405. (Pubitemid 27342428)
18. Eggimann, P., J. Garbino, and D. Pittet. 2003. Epidemiology of Candida species infections in critically ill non-immunosuppressed patients. Lancet Infect. Dis. 3:685-702. (Pubitemid 37345347)
19. Elguezabal, N., J. L. Maza, M. D. Moragues, and J. Pontón. 2009. Monoclonal antibody-mediated inhibition of adhesion of Candida albicans and Candida dubliniensis to human epithelial cells. Eur. J. Oral Sci. 117:474-478.
20. Reference deleted.
21. Reference deleted.
22. Grappel, S. F., and R. A. Calderone. 1976. Effect of antibodies on the respiration and morphology of Candida albicans. S. Afr. Med. J. 14:51-60.
23. Reference deleted.
24. Han, Y. 2010. Efficacy of combination immunotherapy of IgM MAb B6.1 and amphotericin B against disseminated candidiasis. Int. Immunopharmacol. 10:1526-1531.
25. Han, Y., and J. E. Cutler. 1995. Antibody response that protects against disseminated candidiasis. Infect. Immun. 63:2714-2719.
26. Han, Y., T. Kanbe, R. Cherniak, and J. E. Cutler. 1997. Biochemical characterization of Candida albicans epitopes that can elicit protective and nonprotective antibodies. Infect. Immun. 65:4100-4107. (Pubitemid 27422065)
27. Han, Y., et al. 2001. Complement is essential for protection by an IgM and an IgG3 monoclonal antibody against experimental hematogenously disseminated candidiasis. J. Immunol. 167:1550-1557. (Pubitemid 32703155)
28. Han, Y., R. P. Morrison, and J. E. Cutler. 1998. A vaccine and monoclonal antibodies that enhance mouse resistance to Candida albicans vaginal infection. Infect. Immun. 66:5771-5776. (Pubitemid 28531833)
29. Han, Y., M. H. Riesselman, and J. E. Cutler. 2000. Protection against candidiasis by an immunoglobulin G3 (IgG3) monoclonal antibody specific for the same mannotriose as an IgM protective antibody. Infect. Immun. 68:1649-1654. (Pubitemid 30108568)
30. Han, Y., M. A. Ulrich, and J. E. Cutler. 1999. Candida albicans mannan extract-protein conjugates induce a protective immune response against experimental candidiasis. J. Infect. Dis. 179:1477-1484. (Pubitemid 29246598)
31. Hobson, R. P., et al. 2004. Loss of cell wall mannosylphosphate in Candida albicans does not influence macrophage recognition. J. Biol. Chem. 279:39628-39635. (Pubitemid 39258230)
32. Horn, D. L., et al. 2009. Epidemiology and outcomes of candidemia in 2019 patients: data from the prospective antifungal therapy alliance registry. Clin. Infect. Dis. 48:1695-1703.
33. Hsu, F. C., P. C. Lin, C. Y. Chi, M. W. Ho, and J. H. Wang. 2009. Prognostic factors for patients with culture-positive Candida infection undergoing abdominal surgery. J. Microbiol. Immunol. Infect. 42:378-384.
34. Jarvis, W. R., and W. J. Martone. 1992. Predominant pathogens in hospital infections. J. Antimicrob. Chemother. 29:19-24.
35. JAX Mice and Services. 1988. Mice, H-2 haplotypes of mice from Jackson Laboratory colonies, pamphlet. JAX Mice and Services, Jackson Laboratory, Bar Harbor, ME.
36. Kavishwar, A., and P. K. Shukla. 2006. Candidacidal activity of a monoclonal antibody that binds with glycosyl moieties of proteins of Candida albicans. Med. Mycol. 44:159-167. (Pubitemid 43135543)
37. Kobayashi, H., et al. 1991. Candida albicans serotype A strains grow in yeast extract-added Sabouraud liquid medium at pH 2.0, elaborating mannans without β-1,2 linkage and phosphate group. Biochem. Biophys. Res. Commun. 175:1003-1009.
38. Magliani, W., S. Conti, L. Giovati, D. Maffei, and L. Polonelli. 2008. Antibeta-glucan-like immunoprotective candidacidal antiidiotypic antibodies. Front. Biosci. 13:6920-6937.
39. Marsh, J. J., and H. G. Lebherz. 1992. Fructose-bisphosphate aldolases: an evolutionary history. Trends Biochem. Sci. 17:110-113.
40. Matthews, R. C., et al. 2003. Preclinical assessment of the efficacy of mycograb, a human recombinant antibody against fungal HSP90. Antimicrob. Agents Chemother. 47:2208-2216. (Pubitemid 36753574)
41. Mochon, A. B., and J. E. Cutler. 2005. Is a vaccine needed against Candida albicans? Med. Mycol. 43:97-115. (Pubitemid 40439398)
42. Moragues, M. D., et al. 2003. A monoclonal antibody directed against a Candida albicans cell wall mannoprotein exerts three anti-C. albicans activities. Infect. Immun. 71:5273-5279. (Pubitemid 37070774)
43. Nooney, L. M., R. C. Matthews, and J. P. Burnie. 2005. Evaluation of Mycograb, amphotericin B, caspofungin, and fluconazole in combination against Cryptococcus neoformans by checkerboard and time-kill methodologies. Diagn. Microbiol. Infect. Dis. 51:19-29.
44. Pachl, J., et al. 2006. A randomized, blinded, multicenter trial of lipid-associated amphotericin B alone versus in combination with an antibodybased inhibitor of heat shock protein 90 in patients with invasive candidiasis. Clin. Infect. Dis. 42:1404-1413.
45. Pincus, S. H., A. O. Shigeoka, A. A. Moe, L. P. Ewing, and H. R. Hill. 1988. Protective efficacy of IgM monoclonal antibodies in experimental group B streptococcal infection is a function of antibody. J. Immunol. 140:2779-2785.
46. Pitarch, A., et al. 2004. Proteomics-based identification of novel Candida albicans antigens for diagnosis of systemic candidiasis in patients with underlying hematological malignancies. Proteomics 4:3084-3106. (Pubitemid 39372391)
47. Richards, M. J., J. R. Edwards, D. H. Culver, R. P. Gaynes, and National Nosocomial Infections Surveillance System. 1998. Nosocomial infections in coronary care units in the United States. Am. J. Cardiol. 82:789-793.
48. Rodaki, A., T. Young, and A. J. Brown. 2006. Effects of depleting the essential central metabolic enzyme fructose-1,6-bisphosphate aldolase on the growth and viability of Candida albicans: implications for antifungal drug target discovery. Eukaryot. Cell 5:1371-1377.
49. Son, Y.-I., et al. 2002. A novel bulk-culture method for generating mature dendritic cells from mouse bone marrow cells. J. Immunol. Methods 262:145-157. (Pubitemid 34450739)
50. Torosantucci, A., et al. 2005. A novel glyco-conjugate vaccine against fungal pathogens. J. Exp. Med. 202:597-606. (Pubitemid 41258184)
51. Torosantucci, A., et al. 2009. Protection by anti-beta-glucan antibodies is associated with restricted beta-1,3 glucan binding specificity and inhibition of fungal growth and adherence. PLoS One 4:e5392.
52. Xin, H., and J. E. Cutler. 2006. Hybricoma passage in vitro may result in reduced ability of antimannan antibody to protect against disseminated candidiasis. Infect. Immun. 74:4310-4321.
53. Xin, H., S. Dziadek, D. R. Bundle, and J. E. Cutler. 2008. Synthetic glycopeptide vaccines combining β-mannan and peptide epitopes induce protection against candidiasis. Proc. Natl. Acad. Sci. U. S. A. 105:13526-13531.
54. Yang, Q., et al. 2005. Prophylactic vaccination with phage-displayed epitope of C. albicans elicits protective immune responses against systemic candidiasis in C57Bl/6 mice. Vaccine 23:4088-4096. (Pubitemid 40800671)